Retatrutide

Summary

Retatrutide (developmental code LY3437943) is an investigational once-weekly injectable from Eli Lilly being developed for obesity. It is a first-in-class "triple agonist": a single molecule that activates the receptors for three metabolic hormones — GLP-1, GIP, and glucagon — where the approved drugs semaglutide (GLP-1) and tirzepatide (GLP-1/GIP) hit only one or two. In trials it has produced the largest average weight loss reported for any obesity medication to date. The crucial caveat is that, as of mid-2026, retatrutide is not approved anywhere and is legally available only to people enrolled in Lilly's clinical trials — so any "retatrutide" sold online is unapproved gray-market product, which is a very different risk picture from the trial drug.

What people use it for

In clinical development, retatrutide is being studied for obesity and overweight (with and without related conditions), type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, fatty liver disease (MASLD), chronic low back pain, and cardiovascular/renal outcomes. In the gray market and biohacker communities, it is bought and injected primarily for rapid weight loss and body recomposition, and sometimes promoted for metabolic-health and "longevity" goals. The evidence sections below describe what the trials have actually shown versus what online use assumes.

Human evidence

Unlike most peptides covered here, retatrutide has substantial, high-quality human trial data — because it is a pharmaceutical company's drug candidate, not a gray-market compound, and has been run through formal trials.

In the Phase 2 trial (Jastreboff et al., published in the New England Journal of Medicine in 2023; 338 adults with obesity or overweight without diabetes), 48 weeks of treatment produced a mean weight reduction of up to about 24.2% at the highest dose (12 mg), with participants still losing weight when the study ended. It was a multicenter, randomized, double-blind, placebo-controlled trial. A secondary finding was a large reduction in liver fat.

Phase 3 results (Lilly's TRIUMPH program, which has enrolled more than 5,800 participants) have begun reporting and are consistent with Phase 2. TRIUMPH-4 (reported December 2025), in people with obesity and knee osteoarthritis, showed substantial weight loss plus reductions in knee pain. TRIUMPH-1 (topline reported May 2026; about 2,339 adults with obesity, no diabetes required) reported up to roughly 28.3% mean weight loss at 80 weeks at the 12 mg dose, with a subgroup in an extension reaching about 30.3% at 104 weeks — a level of weight loss that approaches what bariatric surgery achieves.

Two honest caveats on the Phase 3 data: at the time of writing, the TRIUMPH-3 (cardiovascular disease) and several other readouts are still pending, and the Phase 3 topline numbers come from company press releases ahead of full peer-reviewed publication, so the detailed data and independent scrutiny are still to come. The Phase 2 data, by contrast, is fully peer-reviewed.

Independent synthesis backs up the trial findings. A 2025 systematic review and meta-analysis of randomized controlled trials (Abouelmagd et al., Proceedings (Baylor University Medical Center)) pooled the available retatrutide RCT data and concluded that the drug produced significant, dose-dependent reductions in body weight and improvements in metabolic markers versus placebo, with a side-effect profile dominated by dose-related gastrointestinal effects. A meta-analysis is a step up from any single trial because it aggregates results across studies — though here it necessarily reflects the early (mostly Phase 1/2) data available when it was written, not the newer Phase 3 readouts.

Animal / preclinical evidence

Retatrutide's preclinical and early pharmacology are documented in its original discovery paper (Coskun et al., Cell Metabolism, 2022), which described the molecule "from discovery to clinical proof of concept" — characterizing it as a single peptide engineered to activate the GIP, GLP-1, and glucagon receptors, and reporting preclinical (animal) and first-in-human data. The therapeutic rationale is that adding glucagon-receptor activity to the GLP-1/GIP combination increases energy expenditure and may drive greater fat loss (including liver fat) than the dual agonists — which is the leading explanation offered for the larger weight-loss numbers seen later in human trials. Animal studies have shown retatrutide delaying gastric emptying, reducing food intake, and producing weight loss. For a drug this far into human testing, though, the preclinical data is mainly of mechanistic and historical interest; the human trials above are the evidence that matters for whether it works in people.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Because the trial results have been widely publicized, retatrutide has a substantial online following, and gray-market "reta" is bought and self-injected for weight loss well ahead of approval. Community reports describe strong appetite suppression and rapid weight loss, along with the gastrointestinal side effects typical of this drug class. These reports cannot be treated as evidence of either efficacy or safety for the products actually being sold, because gray-market vials are unregulated: purity, dose accuracy, and even identity are unverified, and self-dosing happens without the medical monitoring, dose-escalation schedule, and screening used in the trials.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The TRIUMPH Phase 3 program has tested once-weekly doses of retatrutide reported as 2 mg, 4 mg, 6 mg, 9 mg, and 12 mg, reached through gradual dose escalation; the Phase 2 trial used 1, 4, 8, and 12 mg arms. The largest weight-loss figures came from the highest (12 mg) dose. These figures describe what was administered in monitored clinical trials with a defined escalation schedule — they are reported here for context only and are not a protocol to follow, particularly given that no approved, quality-controlled product exists.

Safety & side effects

In the trials, retatrutide's most common adverse events were gastrointestinal — nausea, vomiting, and diarrhea — generally mild to moderate and most frequent during dose escalation, consistent with the incretin (GLP-1-based) drug class; the overall safety profile was described as similar to other incretin therapies, though the rate of GI effects appears higher than with the dual agonists. Some analyses have noted dose-dependent increases in heart rate (also seen with related drugs) and other class effects, and the long-term safety profile and cardiovascular-outcome data are still being collected in ongoing Phase 3 trials. Importantly, all of this safety information comes from monitored trials using pharmaceutical-grade drug. It does not transfer to gray-market "retatrutide," where contamination, incorrect dosing, and misidentified contents are realistic and serious risks, and where there is no clinician managing escalation or screening for contraindications.

Regulatory / legal status

As of mid-2026, retatrutide is investigational and not approved by the FDA, the EMA, or any major regulator. It is in Phase 3 development, and Lilly has indicated a regulatory submission is anticipated around late 2026 at the earliest, meaning any approval decision would come later still. Lilly states plainly that retatrutide "is legally available only to participants in Lilly's clinical trials." This is a key difference from already-approved GLP-1 drugs: because retatrutide is not approved and not on any compounding list, there is no legal prescription or compounding pathway for it at all — so every non-trial source is, by definition, unapproved gray-market product. Status can change as trials report and a filing proceeds; this is not legal or medical advice.

Podcast / media mentions

Retatrutide gets heavy coverage in obesity-medicine and biohacking media because the weight-loss numbers are genuinely striking, and that coverage is largely accurate about the efficacy. The discussion worth scrutinizing is the slide from "the trial drug works extremely well" to "so you should buy reta online now" — those are very different propositions, and the second one inherits none of the trials' safety controls or product quality.

On the Huberman Lab podcast episode "Peptides: The Science, Uses & Safety" (June 1, 2026), physician Dr. Abud Bakri discusses retatrutide in a segment beginning around 2:33:53, framed alongside drug-patent and naming considerations. As a general principle for this kind of coverage: where a physician accurately conveys that retatrutide is a powerful but still-investigational drug that isn't legally available outside trials, that squares with the evidence; where any source implies the online gray-market version is equivalent to the trial drug, that does not.